When rubber stamped by the European Commission in a few months, the CHMP’s label expansion for Viekirax/Exviera should increase ABBV/ENTA’s market share in the EU, which is a predominantly GT1b market where Viekirax/Exviera already has a market share in the mid twenties (#msg-128526031).
However, the sales uplift for ABBV/ENTA from having an 8-week option for Viekirax/Exviera will be relatively short-lived insofar as ABBV/ENTA’s pan-genotypic G/P will be on the market in many EU countries within the next year or so (#msg-127281791), cannibalizing sales of Viekirax/Exviera.
*The EU brand name for Viekira Pak.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.